Heart disease remains the major cause of death in males and females, emphasizing the need for novel strategies to improve patient treatment and survival. A therapeutic approach, still in its infancy, is the development of site-specific drug-delivery systems. Nanoparticle-based delivery systems, such as liposomes, have evolved into robust platforms for site-specific delivery of therapeutics. In this review, the clinical impact of cardiovascular disease and the pathophysiology of different subsets of the disease are described. Potential pathological targets for therapy are introduced, and promising advances in nanotherapeutic cardiovascular applications involving liposomal platforms are presented. © 2013 Ruiz-Esparza et al, publisher and licensee Dove Medical Press Ltd.
CITATION STYLE
Ruiz-Esparza, G. U., Flores-Arredondo, J. H., Segura-Ibarra, V., Torre-Amione, G., Ferrari, M., Blanco, E., & Serda, R. E. (2013, February 7). The physiology of cardiovascular disease and innovative liposomal platforms for therapy. International Journal of Nanomedicine. https://doi.org/10.2147/IJN.S30599
Mendeley helps you to discover research relevant for your work.